COPD is progressive. Is their current therapy alone enough?
- GOLD guidelines support
- — Adding 1 or more classes of long-acting bronchodilar when necessary1
- — A stepwise approach, adding inhaled glucocortiscosteroids only the most severe cases1
- Anticholinergics induce prolonged broncholation2,3
- LABAs contribute a rapid onset with greater peak effect2,3
- —Provide relief within minutes4,5
Twice-daily BROVANA® (arformoterol tartrate) may be the right fit
GOLD guidelines recommend adding one or more classes of long-acting bronchodilators when necessary1
Mean change in FEV1 from study baseline at Week 2 in a 2-week, prospective, multicenter, randomized, modified-blind, double-dummy, parallel-group study designed to evaluate the efficacy and safety of the combination of nebulized BROVANA® (arformoterol tartrate) Inhalation Solution 15 mcg twice daily and tiotropium 18 mcg once daily am vs the individual monotherapies in the treatment of COPD patients (N=234).
* Dosed sequentially. COPD patients instructed to use nebulizer first, followed immediately (within 5 minutes) by the DPI.6
- The addition of BROVANA® (arformoterol tartrate) to tiotropium was more effective in improving lung function and disease symptoms than either monotherapy6
- Occurrence of headache was greater in the BROVANA/tiotropium group (5.1%) than in the BROVANA (1.3%) or tiotropium (3.8%) monotherapy groups7
- Percentage of patients with change from baseline in heart rate of >25 bpm was greater in the BROVANA/tiotropium group (14.1%) than in the BROVANA (7.9%) or tiotropium (6.3%) monotherapy groups. Systolic blood pressure (SBP) >180 mm Hg and diastolic blood pressure (DBP) >105 mm Hg were greater with BROVANA/tiotropium therapy than with either monotherapy. SBP >180 mm Hg occurred in 3.9%, 2.5%, and 6.4% of COPD patients in the BROVANA, tiotropium, and BROVANA/tiotropium groups, respectively. DBP >105 mm Hg occurred in 2.6%, 3.8%, and 5.1% of COPD patients, respectively7
- Treatment-emergent adverse events (AEs) occurred in 25.0%, 27.5%, and 30.8% of COPD patients in the BROVANA, tiotropium, and BROVANA/tiotropium therapy groups, respectively
- The most frequently reported adverse events among COPD LABA patients were diarrhea, nausea, chest pain, bronchitis, dizziness, headache, cough, nasal congestion, pharyngolaryngeal pain, and hypertension7
When you want them to get back into daily living, BROVANA® (arformoteral tartrate) may be the right fit for COPD maintenance therapy
BROVANA® (arformoterol tartrate) Inhalation Solution should not be used in conjunction with other inhaled, long-acting beta2-agonists. BROVANA should not be used with other medications containing long-acting beta2-agonists.
All LABA, including BROVANA® (arformoterol tartrate), are contraindicated in patients with asthma without use of a long-term asthma control medication.
BROVANA® (arformoterol tartrate), as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.